Morgan Matthews, | |
780 W Bel Air Ave Ste B, Aberdeen, MD 21001-2236 | |
(410) 273-1030 | |
Not Available |
Full Name | Morgan Matthews |
---|---|
Gender | Female |
Speciality | Licensed Practical Nurse |
Location | 780 W Bel Air Ave Ste B, Aberdeen, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1497225213 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | LP53351 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Morgan Matthews, 780 W Bel Air Ave Ste B, Aberdeen, MD 21001-2236 Ph: () - | Morgan Matthews, 780 W Bel Air Ave Ste B, Aberdeen, MD 21001-2236 Ph: (410) 273-1030 |
News Archive
Scientists are one step closer to unraveling the complex mechanisms in the brain that regulate body weight. Working with mice - whose appetites are controlled by systems very similar to those in humans – they have identified a specific type of neuron that is essential for feeding behavior.
In a recent issue of Psychotherapy and Psychosomatics a group of German investigators headed by Eva Brakemeier has performed a pilot study to test a new approach for chronic depression.
New research helps bridge an important gap in understanding schizophrenia, providing the best evidence to date that defects in the brain's white matter are a key contributor to the disease, which affects about 1 percent of people worldwide.
NPR began a series called "Is That So?": "As the debate about the health overhaul bill goes on (and on and on) you might find that sometimes what one Senator says seems to be the exact opposite of the next." In the first installment, NPR's Julie Rovner examined Sen. Christopher Dodd's statement: "On the day this bill is enacted, health insurance becomes a buyer's market, not a seller's market. And that's as American as apple pie," and found that "it may be so eventually, but definitely not on the day the bill is enacted."
Results of a study by investigators at St. Jude Children's Research Hospital provide strong evidence for why the drug imatinib (Gleevec), which has revolutionized the treatment of chronic myelogenous leukemia (CML), is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL).
› Verified 2 days ago